Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

BACKGROUND: Oncotype DX (ODX) is a validated assay for the prediction of risk of recurrence and benefit of chemotherapy (CT) in both node negative (N0) and 1–3 positive nodes (N1), hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) early breast cancer (eBC). D...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Leandro Jonata Carvalho, Megid, Thais Baccili Cury, Rosa, Daniela Dornelles, Magliano, Carlos Alberto da Silva, Assad, Daniele Xavier, Argolo, Daniel Fontes, Sanches, Solange Moraes, Testa, Laura, Bines, José, Kaliks, Rafael, Caleffi, Maira, de Melo Gagliato, Debora, Sahade, Marina, Barroso-Sousa, Romualdo, Corrêa, Tatiana Strava, Shimada, Andrea Kazumi, Batista, Daniel Negrini, Musse Gomes, Daniel, Cesca, Marcelle Goldner, Gaudêncio, Débora, Moura, Larissa Matos Almeida, de Araújo, Julio Antonio Pereira, Katz, Artur, Mano, Max Senna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806428/
https://www.ncbi.nlm.nih.gov/pubmed/36601632
http://dx.doi.org/10.1177/17588359221141760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806428/
https://www.ncbi.nlm.nih.gov/pubmed/36601632
http://dx.doi.org/10.1177/17588359221141760

Ejemplares similares